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Introduction
Infections caused by Streptococcus Pneumoniae are a major cause 
of morbidity and mortality all over the world. Pneumonia, 
febrile bacteraemia and meningitis are the most common mani-
festations of invasive pneumococcal disease. The World Health 
Organization (WHO) estimates that up to one million children 
under five die each year from pneumococcal diseases.1 Most of 
these deaths occur in developing countries where pneumococ-
cus is probably the most important pathogen of early infancy. 
Currently a 7-valent Pneumococcal Conjugate Vaccine (PCV), 
manufactured by Wyeth, is available. Availability of 10- and 
13-valent vaccines are expected in the next 1–2 years.2
Introduction: pneumococcal conjugate vaccines are expensive relative to those in the epI systems of low-income coun-
tries. The current single-dose presentation costs more to store in the cold chain relative to multi-dose presentations but 
also has lower wastage rates. It is, therefore, important to determine the optimal balance of vial size and storage costs 
after adjusting for wastage.
Objectives: To project the cost implications of wastage when vaccine wastage rates vary across vial sizes using country 
specific wastage data.
Results: Only 19 (26%) of 72 GaVI eligible countries had analyzable wastage data at WHO/HQ. The median wast-
age rates for single, 2- and 10-dose vials were 5%, 7% and 10% respectively. However wastage varied between 1–10%, 
1–27% and 4–44% for single, 2- and 10-dose vials respectively. The increased variance for multi-dose vial wastage implied 
wastage costs potentially greater than the savings realized from lower storage volumes.
Methods: For each potential vial size, we estimated cold chain costs and the cost of wasted vaccine doses using country 
level wastage data and projections of the price per dose of vaccine and cold chain storage.
conclusions: The optimal vial-size for PCV is dependent upon country specific wastage rates but few countries have 
these data. There may be a role for both single and multi-dose vials that is best determined by local management and 
storage capacities making local wastage data critical. Without effective wastage monitoring and control there is a risk that 
wastage costs will possibly exceed the savings from multi-dose vials’ lower storage costs.
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New vaccines such as PCV are expensive and are expected to 
cost 5–$7 per dose in developing countries3 and 3 doses of PCV 
are required for each child. It has, therefore, become exceedingly 
important to determine its optimal vial size. Vial size refers to the 
size of the vial in which the vaccine is supplied. Multi-dose vials 
can have 2, 5, 6, 10, 20, etc. doses of vaccine in a vial while a sin-
gle-dose vial has just one dose of the vaccine. The manufacturing 
costs in a multi-dose vial are spread over many doses and there-
fore they tend to cost less per dose as compared to a single-dose 
vial. Further multi-dose vials have lower cold chain costs however 
they are also thought to be associated with higher wastage.
There is very limited literature examining the preferred vial 
size for EPI vaccines. In Madagascar, a mixed solution was found 
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According to the MDVP of WHO, multi-dose vials of vac-
cines like Hib, DTP and HepB from which one or more doses 
of vaccine have been removed during an immunization session 
can be used for up to 4 weeks if kept under appropriate con-
ditions like cold chain. This is applicable for only liquid vac-
cines that contain preservatives. The 2-dose wastage rates are for 
DTPHepBHib pentavalent liquid + lyophilized (LLy) vaccine. 
Once opened and reconstituted, the vaccine must be used imme-
diately and any unused doses have to be discarded. The 10-dose 
vial rates are all for liquid vaccines which can be used for longer 
periods. MDVP may therefore be responsible for the low 10-dose 
vial wastage, diminishing the vial size effect. Currently, we are 
not aware of any manufacturer intending to use a preservative in 
the liquid PCV vaccine and so we believe that wastage rates for 
a 10-dose PCV vial would be higher than those shown here; the 
2-dose vial wastage would be similar.
Vaccine costs. To see the impact of wastage on PCV, two-
way sensitivity analyses varying the wastage rates for single-
dose vials with those of 2 and 10-dose vials were conducted, 
Figure 1. Wastage for single-dose vial was varied from 0–10% 
while 0–20% for a multi-dose vial of PCV. The graph shows the 
pair wise comparisons of PCV costs between a single and a multi-
dose vial at different wastage rates. Since we do not anticipate 
that any country should have more than 10% wastage using a 
single-dose vial, it can be seen that a 2-dose vial is always undesir-
able compared to a single-dose vial, once the 2-dose wastage rates 
exceed 11% (1b). Similarly, a 10-dose vial is always undesirable 
once its wastage exceed 14% (1a).
In Figure 2, we introduce the notion of discounting the price 
per dose for a multi-dose vial as compared to a single-dose vial. 
Holding the price per dose in a single-dose vial at $5, if 10-dose 
vial is $0.25 cheaper per dose (Point A), 10-dose vial wastage 
needs to be 5 percentage points higher than the wastage for a sin-
gle-dose vial in order for the single-dose vial to be cheaper. If the 
difference in wastage is less than 5 percentage points, then the 
10-dose vial is cheaper. Since our limited data suggests that sin-
gle-dose vial median wastage is 5%, this implies that if 10-dose 
vial wastage is higher than 10%, a single-dose vial is cheaper even 
with the $0.25 discount. With a $0.50 discount, the single-dose 
vial does not become more efficient until the 10-dose vial wast-
age exceeds 15%. Note that these results are not adjusted for cold 
chain costs.
The costs expected for different vial-sizes, adjusted for cold 
chain, for Country A are shown in Figure 3. We see that when 
wastage rates are as low as the 25th percentile, the 10-dose vial 
to be most appropriate thus multi-dose vials were recommended 
for routine mass immunization campaigns while single-dose 
vaccines were recommended for non-routine immunization 
days.4 In Bangladesh, it was found that the existing cold-chain 
equipment had enough spare capacity to introduce and sustain 
the storage of single-dose vials of Hepatitis B vaccine.5 This 
would have been of great potential benefit to Bangladesh, which 
has reported very high multi-dose wastage rates, 30–59% at 
ward level for DTP (Diphtheria-Tetanus-Pertussis) and as high 
as 84% for BCG (Bacillus Calmette Guérin).6 A study assessing 
the cost effectiveness of using a single-dose pre-filled Uniject 
HepB presentation in Indonesia found that although the cost 
per injection was lower using vials and syringes, after adjust-
ing for wastage there was no price advantage over the use of a 
Uniject device.7
The first objective of this study is to determine the cost impli-
cations of wastage when wastage rates vary over vial sizes. Using 
simple assumptions about the cost of PCV in different vial sizes, 
we estimate and compare the costs of vaccinating a hypothetical 
birth cohort over a range of wastage rates and vial sizes. This 
analysis helps to put the study in context by showing how much 
vaccine wastage might cost donors/countries if they were to 
introduce PCV at current wastage rates. The second objective is 
to repeat this exercise to estimate the potential cost of wastage for 
specific countries.
Since PCV is a new vaccine, data on wastage rates for PCV 
in any vial size is not available. According to WHO guidelines, 
if the new vaccine is of a similar formulation, follows a similar 
schedule and there is no change in vial size then the wastage rates 
for the existing vaccine can be used to estimate the requirements 
for the new vaccine.8 Therefore the analysis used the wastage rates 
for other vaccines to estimate the likely cost of wastage of PCV in 
different vials. Since PCV is a liquid vaccine, analysis used data 
available from other liquid vaccines as far as possible. Due to lack 
of data if other vaccine formulations are used, the implications of 
using such formulations are stated.
Results
Wastage rates. The availability of country-specific, vial-size spe-
cific and vaccine-formulation specific wastage rate data is very 
limited. From 72 GAVI eligible countries, data was available for 
only 19 countries.
Table 1 shows the range, median, 25th and 75th percentiles for 
wastage rates by vial size and formulation.
Table 1. summary of data on vaccine wastage rates available for 19 GaVI eligible countries
Vial size Range (Min-Max) Percentile Value Median N Formulation
1 1%–10%
p25 5%
5% 7 Liquid1
p75 5%
2 1%–27%
p25 5%
7% 26 Liquid-lyophilized2
p75 11%
10 4%–44%
p25 8%
10% 8 Liquid3
p75 13%
1pentavalent (single-dose vial); 2pentavalent (2-dose vial); 3DTp, DTp-HepB, HepB.
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vaccine is most efficient. However, the extra expense in terms 
of vaccine costs and storage costs when the vaccine wastage rate 
approximates the 75th percentile reverses this result with the sin-
gle-dose vial becoming more efficient. This result holds compar-
ing a single-dose to a 2-dose vial or from a 2-dose to a 10-dose 
vial, regardless of whether 25th or 75th percentile rates are used.
This analysis takes into account the costs of PCV and cold 
chain for only one year. In practice, cost of cold chain is spread 
across several years while the cost of vaccines is incurred yearly. 
Therefore, once cold chain investments are made, the benefits 
of reducing wastage by changing vial size carry over for a longer 
period than has been presented here while the cost of vaccines 
wasted will be incurred for each of those years.
Country specific costs of wastage. Table 2 shows country 
specific costs of vaccine wasted for currently used DTPHepBHib 
pentavalent and hypothetical PCV presentations. Cost of wast-
age for PCV is shown for all countries. Cost of wastage for pen-
tavalent vaccine is only shown for countries where wastage rates 
for pentavalent is known. Pentavalent is chosen for comparison 
as data on wastage rates for this vaccine is known for most of the 
countries included in this analysis.
Using empirical wastage rates, almost $4.5 million worth pen-
tavalent vaccines could have been wasted in Kenya in 2005, when 
the reported wastage rate was 27%. In Bolivia this figure is esti-
mated to be $0.13 million in 2003, with 5% wastage. If Kenya, 
with wastage rate of 27%, were to introduce PCV in a single-dose 
vial, the cost of vaccine wastage would be about $6 million. In 
2006, Kenya reduced its wastage to 5% and at this wastage rate 
Kenya would save almost $0.55million. The purpose of Table 2 
is to illustrate the fact that the absolute cost of wastage can be 
very large and if steps are not taken to control wastage this cost 
will increase when a more expensive vaccine is introduced. This 
table suggests that there can be substantial savings both at the 
country and donor levels if wastage can be rigorously monitored 
and controlled.
Country specific comparisons adjusting for cold chain costs. 
The difference in vaccine and cold chain costs, associated with 
different vial-sizes of PCV were estimated for countries. As wast-
age rates for PCV are not available, wastage rates available for 
other vaccines for that country are used to calculate the cost of 
vaccinating a child with 3 doses of PCV. We present the data for 
Mali, Kenya and Ghana, for which we have more than one avail-
able wastage rate, to illustrate the impact of wastage for different 
vial-sizes (Fig. 4).
For Kenya, at almost any wastage rate (5 to 27%), a sin-
gle-dose vial of PCV would be optimal compared to a 2-dose 
vial, with the costs of procuring excess vaccine far outweighing 
the cost of expanding cold chain capacity, as the 27% rate is 
approached. It is unrealistic to assume that any country can 
reduce wastage to 0% and 5% is probably an acceptable and 
achievable target.
We note that the drop in wastage from 27% to 5% occurred 
within a single year. We have no information as to why this 
occurred. This level of wastage reduction does not appear to 
have been foreseen by even Kenya’s planners as the Financial 
Sustainability Plan (FSP) for Kenya used wastage rates of 
Figure 1. sensitivity analysis: comparing cost per dose of pcV in 
different vial-sizes. (cost does not include the cold chain costs) price 
of pcV: $5/dose (single-dose vial); $5/dose (2-dose vial); $4.80/dose 
(10-dose vial).
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The main finding is that there is insufficient monitoring and con-
trol of vaccine wastage in GAVI eligible countries assuming that 
the data available from the WHO are indeed representative of 
the currently available data for GAVI countries. We were able 
to obtain wastage rate data for only 19 of the 72 GAVI eligible 
countries. Where the available data identified vaccine formula-
tion, vial size was not always specified. This is important as the 
data presented here strongly suggests that wastage differs by vac-
cine formulation and vial size, with lyophilized vaccines having 
higher wastage than liquid and larger vials having higher wastage 
than smaller vials. In addition, we hypothesize that if few coun-
tries are reporting wastage to WHO, it is likely that few coun-
tries are monitoring wastage and therefore wastage is likely to be 
higher in the remaining 74% of GAVI countries not considered 
in this analysis due to the lack of wastage data. Though this is 
most likely the reason for many countries that don’t have vaccine 
wastage data, it needs to be explored further.
22 and 20% for 2005 and 2006 to estimate the requirement for 
DTP-HepB vaccine.9
Ghana on the other hand, had a relatively low wastage for 
2-dose pentavalent vaccines. With wastage of 3% the 2-dose is 
likely to be the cheapest but if the wastage increases to 6%, a 
single-dose vial becomes more cost efficient.
Mali, which had wastage rates for both a 2-dose and a 10-dose 
vial over 2 years, reduced its 10-dose vial wastage rate from 17 to 
8% between 2004 and 2005. This difference in wastage would 
potentially reduce costs by $756,000 or $1.70 per fully vacci-
nated child (FVC) if the vaccine in question was PCV.
Discussion
The main objectives of this study were to determine the cost 
implications of wastage in general, given that wastage is expected 
to vary according to vial size and at a country specific level. 
Figure 2. Two-way sensitivity analysis: comparing cost per dose of pcV in single and 10-dose vials for different price per dose (cost includes cold 
chain costs). From a to e, the price of pcV in single-dose vial is constant at 5$; the optimal vial size will depend on the price/dose of pcV in a 10-dose 
vial and the difference in wastage between the vial-sizes. e.g., point a: single-dose vial costs $5/dose, same as a 10-dose vial; single-dose vial will be 
cheaper if its wastage is at least 5% points lower than that for a 10-dose vial. point B: 10-dose vial costs $4.50/dose; single-dose vial will be cheaper if 
its wastage is at least 10% points lower than that for a 10-dose vial.
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amounting to 41 data points. Ghana and Malawi accounted for 7 
of these points. Malawi was the only country which had regional 
and central surveillance data on opened and closed vial wastage 
to support the estimates of wastage rate. Bangladesh was the only 
country from South East Asia and it is questionable as to whether 
it truly represents the region as it has relatively high wastage rates. 
In addition, Mali, Rwanda, Niger and Kenya each reported sharp 
decreases in their wastage rates within 2–3 years and we are only 
able to hypothesize the reasons for these decreases. It is possible 
that the application of the MDVP lowered wastage in Niger and 
Mali or maybe these countries went through a ‘learning curve’ 
and lowered their wastage as their health workers grew familiar 
with the vaccines. However, DTP was not new to Niger, and 
Rwanda had introduced pentavalent 3 years prior to the wastage 
decrease, suggesting that the learning curve took up to 5 years.
Due to lack of data we were unable to identify the cause of 
wastage. If most of the wastage is occurring due to cold chain 
failures like inadequate infrastructure, power shortages and poor 
maintenance, changing the vial size will not reduce this wastage. 
In fact by using single-dose vials, which are more expensive, the 
cost of wastage from these causes can be further increased.
Due to lack of data only cost of cold-rooms at central level and 
cost of ice-lined refrigerators at the provincial and district levels 
are considered in cold-chain costs. Other cold chain costs like 
transportation and maintenance are not included. These costs are 
underestimated for both multi and single dose-vials but since the 
cold chain requirements of single-dose vials are more, this favours 
single-dose vials more. It should also be noted that the cost of 
expanding cold chain systems is spread across years, but the cost 
of wasted vaccines will be incurred every year.
Materials and Methods
Empirical wastage rates. Vaccine wastage rates for 19 GAVI eli-
gible countries were available from WHO Headquarters, Geneva. 
Vaccines were categorized according to their formulation: liquid 
(L), lyophilized (Ly) or liquid + lyophilized (LLy) and vial size. 
This information was cross-references from the WHO Vaccine 
It is possible that the lack of focus on wastage may be due 
to the fact that the primary objective to date has been to vac-
cinate as many children as possible. The efficiency with which 
this objective is achieved has been secondary, particularly when 
vaccines are relatively cheap (or donor financed). Since PCV is 
relatively expensive, the potential costs of wastage are likely to 
be high. Therefore, there is an urgent need to improve wastage 
monitoring.
This study shows that wastage rates can have a major impact on 
the cost of a FVC when vaccines are expensive. With high wast-
age rates, as seen for multi-dose presentations in many countries, 
countries incur avoidable costs from over-ordering vaccines and 
storing this ‘surplus’. A single-dose vial can avoid these costs.
In general, there is limited donor funding for the maintenance 
and running of a cold chain system compared to what is available 
for vaccine procurement. If countries pay for most or all of their 
own cold chain management it is not unreasonable for them to 
limit cold chain costs to the best of their ability.
Single or multi-dose vials can minimize costs but the optimal 
vial-size choice is very sensitive to country specific wastage rates. 
Since wastage differs across countries, one particular vial-size 
may not be applicable for all countries. The optimal vial-size also 
depends on the immunization coverage, session size and number 
of delivery points. For larger sessions and higher coverage rates a 
multi-dose vial may be more apt. But for smaller sessions if the 
10-dose vial of PCV doesn’t contain a preservative, once opened 
it will have to be used in the same session and any unused doses 
will have to be discarded. In this case the cost of wastage is likely 
to be high. Therefore, the optimal solution may be a mix of dif-
ferent vial sizes. In this analysis, a single-dose vial is compared 
to a 10-dose vial. Further research needs to be done to consider 
other in-between sizes.
Many countries would find it cheaper to introduce 10-dose 
vials upfront when they consider cold chain investment costs. But 
without first analyzing the wastage rates in that country this can 
be an extremely costly solution. For a global or a bilateral donor, 
who is funding PCV in many countries, lack of country-specific 
wastage rates makes a 10-dose vial potentially costly as the cost of 
wastage in countries with higher wastage rates is likely to vastly 
outweigh the savings in cold chain storage costs in countries with 
low rates. Currently, PCV is available only in single-dose pre-
filled glass syringes that are not automatically disabled, which 
leads to increased waste disposal and safety concerns associated 
with the potential reuse of syringes and needles especially for 
developing countries. Moreover, it is provided in packages of 10 
syringes requiring approximately 61.2 cubic centimeters per dose, 
which will require substantial increases in cold chain and deliv-
ery systems and is therefore not a viable solution for most of the 
developing countries.
Further, research is required to study the cost implications 
of increasing shipment frequencies which can reduce volume 
requirements both into and within countries and may provide a 
feasible solution to the cold chain capacity issues.
Study limitations. Data available on wastage rates was 
extremely limited and we were unable to validate the estimates in 
this analysis. Wastage rates were available for only 19 countries, 
Figure 3. cost for a fully vaccinated child (FVc) with 3 doses of pcV, 
adjusted for cold chain costs, country a.
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Table 2. Wastage costs for pentavalent and hypothetical pcV introduction, using country’s empirical wastage rate data
Country Year
Vial size/
vaccine
Vaccine 
type/wastage 
(%)1
Coverage 
(%)
Birth 
cohort 
(‘000)
Total cost of wastage ($) Cost of 
wastage 
per FVC for 
PCV2 ($)Penta PCV
2
Bolivia 2006 1/penta L/1 88 251 12,416 16,555 0.08
Bolivia 2003 1/penta L/5 88 251 130,041 173,388 0.79
Guyana 2005 1/penta L/10 94 13 15,275 20,367 1.67
Honduras 2002 1/penta L/5 91 193 103,991 138,655 0.79
Honduras 2003 1/penta L/5 91 193 103,991 138,655 0.79
Honduras 2006 1/penta L/5 91 193 103,991 138,655 0.79
Nicaragua 2001 1/penta L/10 91 136 153,850 205,133 1.67
Benin 2005 2/penta LLy/13 96 322 484,999 692,855 2.24
Benin 2006 2/penta LLy/11 96 322 401,161 573,088 1.85
Burkina Faso 2006 2/penta LLy/6 97 573 379,123 541,604 0.97
Ghana 2002 2/penta LLy/6 86 659 377,628 539,469 0.96
Ghana 2003 2/penta LLy/3 86 659 182,974 261,392 0.46
Ghana 2004 2/penta LLy/5 86 659 311,378 444,825 0.79
Ghana 2006 2/penta LLy/3 86 659 182,974 261,392 0.46
Kenya 2004 2/penta LLy/15 85 1,351 2,127,825 3,039,750 2.65
Kenya 2005 2/penta LLy/27 85 1,351 4,459,688 6,370,983 5.55
Kenya 2006 2/penta LLy/5 85 1,351 634,614 906,592 0.79
Malawi 2004 2/penta LLy/4 99 513 222,193 317,419 0.63
Malawi 2005 2/penta LLy/4 99 513 222,193 317,419 0.63
Malawi 2006 2/penta LLy/5 99 513 280,665 400,950 0.79
Mali 2006 2/penta LLy/1 90 503 48,014 68,591 0.15
Mongolia 2006 2/penta LLy/11 99 47 57,928 82,755 1.78
Rwanda 2003 2/penta LLy/10 99 372 429,660 613,800 1.67
Rwanda 2004 2/penta LLy/12 99 372 527,310 753,300 2.05
Rwanda 2005 2/penta LLy/11 99 372 477,936 682,766 1.85
Rwanda 2006 2/penta LLy/6 99 372 229,395 327,707 0.89
senegal 2006 2/penta LLy/5 94 406 210,906 301,295 0.79
Uganda 2003 2/penta LLy/10 85 1,294 1,275,668 1,822,383 1.67
Uganda 2004 2/penta LLy/11 85 1,294 1,419,002 2,027,146 1.85
Uganda 2005 2/penta LLy/10 85 1,294 1,275,668 1,822,383 1.67
Uganda 2006 2/penta LLy/10 85 1,294 1,275,668 1,822,383 1.67
Yemen 2005 2/penta LLy/7 89 788 551,155 787,365 1.13
Zambia 2006 2/penta LLy/6 87 425 247,811 354,016 0.96
Bangladesh 2005 10/DTp L/44 92 3,783 - 40,034,084 11.50
cameroon 2006 10/DTpHepB L/12 84 591 - 991,075 2.00
Mali 2004 10/HepB L/17 90 503 - 1,357,445 3.00
Mali 2005 10/HepB L/8 90 503 - 576,307 1.27
Niger 2003 10/DTp L/10 49 607 - 478,883 1.63
Niger 2004 10/DTp L/9 49 607 - 426,258 1.45
Niger 2005 10/DTp L/6 49 607 - 275,103 0.93
Niger 2006 10/DTp L/4 49 607 - 179,581 0.61
1L, liquid; LLy, liquid + lyophilized; 2Hypothetical cost of wastage for pcV calculated by using country specific estimates for coverage, wastage rate and 
birth cohort.
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every year there will be 2 shipments to the central level, 4 ship-
ments to the provincial level and 6 shipments to the district 
level. At the central level, cold room costs are calculated while 
at the provinces and districts, costs of ice-lined refrigerators 
are considered. Cold chain estimates ideally should include the 
costs of running the equipment, maintenance and other mis-
cellaneous like transportation. We did not include these costs 
and have likely underestimated cold chain costs for both sin-
gle and multi-dose vials. This underestimation favours single- 
dose vials as they have a greater impact on cold chain 
requirements.
Packaged volume estimates for future possible PCV presen-
tations considered for this analysis are shown in Table 3.
The storage volume factors used to determine the size of cold 
rooms are also shown in Table 3. This factor is used to account 
for air circulation and movement.11 Cost of refrigeration is 
taken as $11.50 per liter (1 liter: 1,000 cm3) from the WHO 
Performance, Quality and Safety (PQS) standards.12
Preventable Disease Monitoring System 2007 Global Summary, 
GAVI/VF shipment records and Financial Sustainability Plans. 
Wastage rates were available for DTP, Hib, HepB, measles, BCG, 
OPV, DTPHib, DTPHepBHib and yellow fever.
As the PCV under consideration is for administration to 
infants, wastage rates only for those vaccines that are adminis-
tered to infant were introduced. Wastage rates for OPV were not 
included since it is an oral vaccine. For the Democratic Republic 
of Congo only combined wastage rates for 10 and 20-dose vials 
of DTP are available; we therefore did not include this wastage 
rate in the analysis.
The wastage rate for a pre-filled syringe presentation was set 
at 1%.7
Cold-chain costs. Cold-chain costs were calculated at three 
levels—central, provincial and district. It was assumed that 
the birth cohort is evenly distributed amongst provinces and 
districts. Therefore the vaccine storage requirement in each 
province and district will be the same. It was assumed that 
Figure 4. country summaries (a, Mali; B, Kenya; c, Ghana): cost for a fully vaccinated child (FVc) with three doses of pcV (adjusted for wastage 
and cold chain costs).
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single-dose vials was varied from 0–10%, and 0–20% for multi-
dose vials. In addition, sensitivity analyses were conducted to 
account for the fact that it is unclear at present what the level of 
discount in price per dose would be if PCV were to be available 
in a multi-dose vial.
Country specific analyses: vial size and cold chain capacity. 
Country specific analyses were conducted to estimate the impact 
of wastage and vial sizes on cost per FVC. For each country, cost 
of wastage, not adjusting for cold chain, was calculated by using 
country specific figures for wastage rate, birth cohort and immu-
nization coverage. Wastage costs were estimated for hypothetical 
PCV presentation for all countries for which empirical wastage 
rates were available, assuming the country used the same vial as 
the one for which wastage rate was available. Wastage costs were 
also estimated for pentavalent vaccines for countries that were 
using this vaccine. Wastage rates for pentavalent vaccine were 
available for most of the countries analyzed here; therefore this 
vaccine was used for comparison.
For Mali, Ghana and Kenya empirical wastage rates were 
available for more than one year or vial size; we, therefore, com-
pared the cost of using a single-dose vial of PCV with the costs of 
using the specific vial sizes for which the rates are available.
Conclusions
Prior to the introduction of PCV in GAVI eligible countries, 
there is an urgent need for more rigorous and systematic wastage 
monitoring. The optimal vial-size for PCV is dependent upon 
country specific wastage rates, coverage levels, current cold chain 
capacities and session sizes. The use of multi-dose vials can result 
in huge wastage, increasing the total vaccine costs and the savings 
associated with their lower volume per dose can only be realized 
in countries with very low wastage.
Vaccine purchase price. The expected purchase price for 
pneumococcal vaccines is projected to be $5–$7 per dose.3 Table 
3 lists the purchase price per dose for all vial sizes considered. 
Prices for a single and a 2-dose pentavalent vaccine are taken as 
$3.75 and $3.50 per dose, 2007 UNICEF prices.13
Methodology. The empirical data were used to determine 
a ‘range’ of wastage rates (with a lower bound at the 25th per-
centile and an upper bound at the 75th percentile) and median 
wastage rates. These bounds were estimated for Ly, L and LLy 
formulations.
Cost per fully vaccinated child. Doses of PCV required are 
calculated according to the WHO Guidelines:10
No. of doses required = i * b * d * [1/(1 - w)]
where,
i = immunization coverage rate;
b = birth cohort;
d = number of doses per fully vaccinated child (FVC);
w = wastage rate (%);
The average of the vaccine coverage rates for DTP1 and DTP3, 
WHO-UNICEF 2006 estimates were used.14 WHO 2006 live 
birth estimate was used for birth cohort. It was assumed that a 
FVC would be one who has received 3 doses of PCV.
Cost per FVC = (No. of doses required * Price per dose) ~ 
(Coverage * Birth Cohort).
Sensitivity analysis. Since data on wastage rates was limited, 
we conducted two-way sensitivity analyses varying the wastage 
rates for all vial sizes. We compared the cost of purchasing PCV 
for a hypothetical country (Country A) with a birth cohort of 1 
million infants and 100% coverage rate. The cost of vaccinating 
this cohort using PCV in a single-dose vial was compared with 
the cost of vaccinating using 2, 5 or 10-dose vials. Wastage for 
Table 3. estimates for purchase price, packaged volume and cost of cold rooms for pcV
(A)
Vial Size
Purchase price 
per dose1
Packaged volume per 
dose (cm³/dose)
Comparable vaccine presentation to estimate  
packaged  volume per dose
1 $ 5.00 12.9b pentavalent (liquid) single-dose vial Berna Biotech Korea corp.
2 $ 5.00 6.4a assumed same vial size as single-dose vial
5 $ 4.88 8.0a assumed same vial size as 10-dose vial
10 $ 4.80 4.0b HepB (liquid) 10-dose vial WHO International shipping Guidelines
pre-filled syringe $ 5.95 55.4b pVc-7 pre-filled syringe, Wyeth
(B)
Cold room size 
(m³)
Volume factorc Cost of cold room ($)
5 3.2 11,000
10 3.3 13,000
15 3.7 14,500
20 3.9 16,000
30 4.2 18,000
40 4.2 20,000
aGaVI’s pneumoaDIp estimates; bWHO Vaccine Volume calculator 2005;10 cWHO Guidelines for establishing or Improving primary and Intermediate 
Vaccine store, 2002.11
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